Abstract:3116 Background: Radiotherapy is one of the standard modalities for the treatment of cancer. Irradiation causes not only tumor cell death, but also can up-regulate tumor antigen and MHC class I molecule expression, thereby promoting the accumulation and activation of immune cells in tumor tissue. We hypothesize that activated CD4+ T cells (aCD4) can presensitize tumor cells and enhance gamma-irradiation -induced cytotoxicity. The rationale is that aCD4 release multiple cytokines, which may regulate gene-expression in tumor cells, thereby affecting their proliferation and apoptosis. Methods: Human cervical carcinoma cell line Hela was used as our initial tumor model. Hela cells were irradiated with 4 Gy after presensitization with aCD4 for 48 hours. The cells were cultured for 2 or 5 more days for apoptosis and cell proliferation assays, respectively. Transwell system was used to determine whether cell contact, soluble factors released by aCD4, or both were essential in this model. Several cytokines including IFN- γ were used to replace aCD4 to determine the contribution of each cytokine. Other cancer cell lines used to validate the strategy included cervical carcinoma cell line Caski, glioma cell lines LN229 and U373, and prostate carcinoma cell line DU145. Results: For Hela cells, growth inhibition was 25.8 ±3.3% in group treated with irradiation alone, 31.5±11.3% in group treated with aCD4 alone, and 60.5±1.3% in the combination group; while the percentage of apoptotic cells as determined by flow cytometry assay using Annexin V was 7.15±0.6%, 9.25±0.4% and 15.65±4.6%, respectively. Similar results were also obtained with other cancer cell lines. For example, for DU145, cell growth inhibition was 35.4±4.0 % in group treated with irradiation alone, 32.65±2.7% in group treated with aCD4 alone, and 70.3±0.14% in the combination group. This effect was aCD4 and irradiation dose dependent. Transwell experiments showed that soluble factors secreted by aCD4 were responsible for the observed activity. Of the cytokines tested, IFN-γ was found to play major role in our model. Growth inhibition was 10.15±1.0% in group treated with IFN- γ alone and 57.03±1.9% in the IFN- γ and gamma-irradiation combination group. Conclusion: We have demonstrated that aCD4 can act as a radiosensitizer to enhance the cytotoxic effect of gamma irradiation in multiple cancer cell lines. Soluble factors released by aCD4 were essential in this effect. IFN- γ was found to play a major role. We are currently working on the mechanism underlying the observed activity. In a separate project, we have also demonstrated great synergism when chemotherapy was given after tumor cells had been presensitized with activated immune cells.

Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration

The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1

Inhibiting the CD8+ T Cell Infiltration in the Tumor Microenvironment after Radiotherapy is an Important Mechanism of Radioresistance

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Abstract LB-251: Radiotherapy Sensitizes Pancreatic Cancer to Immunotherapy by Promoting T Cell Infiltration

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity Via MIF-Induced Functional Orchestration of Tumor-Associated Macrophages

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment

Synergistic effect of radiotherapy and dendritic-cell-based immunotherapy via miR-15b-5p regulation in a colon carcinoma mouse model

DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model

Irradiated Engineered Tumor Cell-Derived Microparticles Remodel the Tumor Immune Microenvironment and Enhance Antitumor Immunity.

Irradiation and Anti-Pd-l1 Treatment Synergistically Promote Antitumor Immunity in Mice.

Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites

Activated CD4+ T Cells As Radiosensitizer: Enhancement of Irradiation-Induced Cytotoxicity by Pretreatment of Tumor Cell with Activated CD4+ T Cells

Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance

Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy

IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion

DPP4 promotes an immunoenhancing tumor microenvironment through exhausted CD8+ T cells with activating IL13-IL13RA2 axis in papillary thyroid cancer

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1